CIS is First to Implant New Orsiro® Mission Coronary Artery Stent in Ambulatory Surgery Setting

Orsiro Mission First

Pictured from left to right are Brice Chauvin, RN with Biotronik, Inc. and CIS interventional cardiologists Dr. Erica Fidone and Dr. Craig Walker.

HOUMA – Interventional cardiologists Drs. Craig Walker and Erica Fidone are the first in the country to implant the Orsiro® Mission Coronary Artery Drug Eluting Stent (DES) by BIOTRONIK, Inc. in an ambulatory surgery setting. The procedure took place on January 7 at the Cardiovascular Institute of the South (CIS) Ambulatory Surgical Center in Gray, Louisiana to treat coronary artery disease.

Orsiro® Mission is a new drug-eluting stent system that offers advanced deliverability and an ultrathin strut design considered the thinnest available in the United States. It features the same proprietary design and innovative bio-absorbable coating with controlled drug release as the Orsiro® stent. Advantages include a re-engineered delivery system and a new deep embedding process to improve deliverability. Ultimately, this new system is designed for easy delivery by skilled cardiologists to open challenging lesions and restore blood flow to the coronary arteries of the heart.

“When patients experience a blockage in the coronary arteries of their heart, the right stent is needed to open the artery,” explained Dr. Walker. “Drug-eluting stents such as the Orsiro® Mission restore blood flow to the heart muscle, and can relieve symptoms of chest pain as well. The design makes it easy to deliver so that we can continue giving our patients the most advanced treatment options.”

To schedule an appointment with a CIS cardiologist, click below. 



Latest News

CIS Staff

Written by CIS Staff